SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating significant community buzz and price volatility as investors push to break through resistance levels and secure a chart listing on tracking platforms. The project is being championed by an active developer and a dedicated base of holders who are heavily promoting the coin across social media to fuel a potential breakout.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy token, associated with the controversial EV stock legacy, is currently generating debate as community members push for renewed momentum and higher market valuations despite significant skepticism from those labeling it a pump-and-dump scam. Investors are actively discussing entry points, sharing contract addresses for Solana-based trading, and comparing the project's volatile history to broader market trends.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is capturing investor attention as the company advances its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, with the community actively monitoring positive clinical trial data and potential breakthrough developments in cardiac and soft tissue treatment. Investors are closely tracking strategic insider activity and long-term clinical trial milestones, frequently discussing the potential for a transformative breakthrough in the atrial fibrillation market.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is seeing heightened interest as investors weigh its potential for institutional adoption, with many pointing to upcoming ETF developments and its performance compared to other Layer 1 networks. While some community members are actively accumulating on dips and tracking technical breakout levels, others remain cautious, debating whether recent price action signals a lasting trend reversal or further volatility.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential versus recent price volatility, with many highlighting its post-quantum security features and institutional moves as catalysts for future growth. While some traders are actively monitoring entry points for accumulation, others are expressing frustration over the project's extended drawdown and shifts in the broader digital asset landscape.

BioLLM

BioLLM is generating significant buzz as the first neuron-integrated language model, with community members actively sharing project updates and development milestones. While supporters are enthusiastic about its novel integration of living cortical neurons, some market participants have expressed skepticism and raised concerns about potential pump-and-dump activity.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently the subject of intense community debate, driven by a mixture of bullish sentiment regarding institutional adoption and significant FUD surrounding the recent Drift protocol exploit. Investors are actively split between those accumulating during market volatility and critics highlighting network reliability concerns, with the community closely tracking how SOL performs relative to broader macroeconomic headwinds.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors remain polarized, with some anticipating significant price appreciation fueled by the potential passage of the Clarity Act and institutional adoption, while others condemn the project as a long-term failure and a scam. Community discourse is dominated by intense debates between 'bag holders' hoping for a breakthrough in payment infrastructure and vocal bears who point to years of consistent decline as evidence that the token has no future.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining significant market attention as community members rally behind its status as an 'OG' meme coin, frequently drawing parallels to other cult-status assets. The conversation is heavily focused on the coin's historical origins, ongoing meme-centric branding, and widespread belief among proponents that it is positioned for sustained long-term growth alongside other community-driven projects.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

The NEOS Nasdaq 100 High Income ETF (QQQI) is seeing strong community interest as investors actively rotate into high-yield, income-focused funds that aim to pair consistent monthly distributions with capital preservation strategies. Enthusiasts are highlighting its tax-efficient return-of-capital structure and ability to provide yield during sideways market conditions, often debating its long-term performance and tactical role compared to broader Nasdaq-100 benchmarks.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of...

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction...

Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today

GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.read more...

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Cyclerion...

Best Pharmaceutical Stocks To Follow Now - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool...

Promising Medical Stocks To Consider - April 1st

Eli Lilly and Company, Cyclerion Therapeutics, Apellis Pharmaceuticals, UnitedHealth Group, Novo Nordisk A/S, Boston Scientific, and Johnson & Johnson are the seven Medical stocks to watch today...

Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics shares are trading sharply higher Wednesday morning after it announced a merger agreement with Korsana Biosciences.read more...

Biotech Reinvention Meets AI’s Buildout Boom

A powerful mix of capital formation, strategic mergers, and infrastructure-scale contracts is reshaping the small- and mid-cap landscape, as companies tied to AI, biotech innovation, and digital infrastructure race to secure relevance, and runway, in an increasingly competitive market. $TGNT, $CYCN, $TH, $SHAZ

<ul class="summary-bullets"><li>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.</li><li>The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.</li><li>Korsana expects the financing round to close immediately prior to the proposed merger.</li></ul>Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Korsana Secures $380M In Commitments To Support Merger</h2>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.The company expects the financing round to close immediately prior to the proposed merger.Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.<h2 class="st-heading-2">What Does Korsana Do?</h2>Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.<a href="https://stocktwits.com/symbol/CYCN">CYCN stock</a> is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ipm-bcg-hubc-stocks-top-premarket-gainers-april-1-2026/cZ7H1jsRInn">IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

Cyclerion stated that it has entered into a definitive merger agreement with Korsana Therapeutics in an all-stock transaction.

Equity

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (Cyclerion) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (Korsana), a privately-held biotechnology company discovering and developing novel therapies to reduce the burden...

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Cyclerion Therapeutics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CYCN
Cyclerion Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CYCN News

CYCNCyclerion Therapeutics Inc